Skip to main content
SpringerLink
Log in

Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

G protein-coupled receptors (GPCRs) are involved in numerous physio-pathological processes, including the stimulation of cancer progression. In this regard, it should be mentioned that although GPCRs may represent major pharmaceutical targets, only a few drugs acting as GPCR inhibitors are currently used in anti-tumor therapies. For instance, certain pro-malignancy effects mediated by GPCRs are actually counteracted by the use of small molecules and peptides that function as receptor antagonists or inverse agonists. Recently, humanized monoclonal antibodies targeting GPCRs have also been developed. Here, we review the current GPCR-targeted therapies for cancer treatment, summarizing the clinical studies that led to their official approval. We provide a broad overview of the mechanisms of action of the available anti-cancer drugs targeting gonadotropin-releasing hormone, somatostatin, chemokine, and Smoothened receptors. In addition, we discuss the anti-tumor potential of novel non-approved molecules and antibodies able to target some of the aforementioned GPCRs in different experimental models and clinical trials. Likewise, we focus on the repurposing in cancer patients of non-oncological GPCR-based drugs, elucidating the rationale behind this approach and providing clinical evidence on their safety and efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639–50.

    Article  CAS  PubMed  Google Scholar 

  2. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. Insights into G protein structure, function, and regulation. Endocr Rev. 2003;24:765–81.

    Article  CAS  PubMed  Google Scholar 

  3. Neves SR, Ram PT, Iyengar R. G protein pathways. Science. 2002;296:1636–9.

    Article  CAS  PubMed  Google Scholar 

  4. Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, Miller RJ, Jan LY, Lefkowitz RJ, Hamm HE. Molecular basis for interactions of G protein betagamma subunits with effectors. Science. 1998;280:1271–4.

    Article  CAS  PubMed  Google Scholar 

  5. Patel TB. Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades. Pharmacol Rev. 2004;56:371–85.

    Article  CAS  PubMed  Google Scholar 

  6. Ribas C, Penela P, Murga C, Salcedo A, García-Hoz C, Jurado-Pueyo M, Aymerich I, Mayor F Jr. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 2007;1768:913–22.

    Article  CAS  PubMed  Google Scholar 

  7. Shenoy SK, Lefkowitz RJ. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 2011;32:521–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Magalhaes AC, Dunn H, Ferguson SS. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol. 2012;165:1717–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. O’Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Aguilar-Rojas A, Pérez-Solis MA, Maya-Núñez G. The gonadotropin-releasing hormone system: perspectives from reproduction to cancer (review). Int J Oncol. 2016;48:861–8.

    CAS  PubMed  Google Scholar 

  12. O’Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J. 2008;409:635–49.

    Article  PubMed  CAS  Google Scholar 

  13. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11:597–606.

    Article  CAS  PubMed  Google Scholar 

  14. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94.

    Article  CAS  PubMed  Google Scholar 

  15. Lappano R, Maggiolini M. GPCRs and cancer. Acta Pharmacol Sin. 2012;33:351–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Richard DE, Vouret-Craviari V, Pouysségur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene. 2001;20:1556–62.

    Article  CAS  PubMed  Google Scholar 

  17. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60.

    Article  CAS  PubMed  Google Scholar 

  18. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25:235–75.

    Article  CAS  PubMed  Google Scholar 

  19. Naor Z, Harris D, Shacham S. Mechanism of GnRH receptor signaling: combinatorial cross-talk of Ca2+ and protein kinase C. Front Neuroendocrinol. 1998;19:1–19.

    Article  CAS  PubMed  Google Scholar 

  20. Gründker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003;7(1):65.

    Article  Google Scholar 

  21. Labrie F. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. Endocr Relat Cancer. 2014;21:R301–17.

    Article  CAS  PubMed  Google Scholar 

  22. McArdle CA. Gonadotropin-releasing hormone receptor signaling: biased and unbiased. Mini Rev Med Chem. 2012;12:841–50.

    Article  CAS  PubMed  Google Scholar 

  23. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33:784–811.

    Article  CAS  PubMed  Google Scholar 

  24. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist. 2000;5:162–8.

    Article  CAS  PubMed  Google Scholar 

  25. Dreicer R, Bajorin DF, McLeod DG, Petrylak DP, Moul JW. New data, new paradigms for treating prostate cancer patients—VI: novel hormonal therapy approaches. Urology. 2011;78:S494–8.

    Article  PubMed  Google Scholar 

  26. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013;9(8):451–66.

    Article  CAS  PubMed  Google Scholar 

  27. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566–77.

    Article  CAS  PubMed  Google Scholar 

  28. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F, European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546–51.

    Article  CAS  PubMed  Google Scholar 

  29. Ploussard G, Mongiat-Artus P. Triptorelin in the management of prostate cancer. Future Oncol. 2013;9:93–102.

    Article  CAS  PubMed  Google Scholar 

  30. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–29.

    Article  PubMed  Google Scholar 

  31. Merseburger AS, Hupe MC. An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv Ther. 2016;33:1072–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Breul J, Lundström E, Purcea D, Venetz WP, Cabri P, Dutailly P, Goldfischer ER. Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer. Adv Ther. 2016. doi:10.1007/s12325-016-0466-7.

    PubMed  PubMed Central  Google Scholar 

  33. Sasse AD, Sasse E, Carvalho AM, Macedo LT. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review. BMC Cancer. 2012;12:54.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:46–52.

    Article  CAS  PubMed  Google Scholar 

  35. Roila F. Buserelin in the treatment of prostatic cancer. Biomed Pharmacother. 1989;43:279–85.

    Article  CAS  PubMed  Google Scholar 

  36. Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol. 1988;11:S176–82.

    Article  PubMed  Google Scholar 

  37. Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1:487–509.

    Article  CAS  PubMed  Google Scholar 

  38. Monahan MW, Amoss MS, Anderson HA, Vale W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry. 1973;12:4616–20.

    Article  CAS  PubMed  Google Scholar 

  39. Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging. 2009;4:259–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Hoda MR, Kramer MW, Merseburger AS, Cronauer MV. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother. 2017;18:105–13.

    Article  CAS  PubMed  Google Scholar 

  41. Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother. 2013;14:2237–47.

    Article  CAS  PubMed  Google Scholar 

  42. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175:533–6.

    Article  CAS  PubMed  Google Scholar 

  43. Schlegel P. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. BJU Int. 2009;103:7–13.

    Article  CAS  PubMed  Google Scholar 

  44. Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol. 2006;175:1353–8.

    Article  CAS  PubMed  Google Scholar 

  45. Dineen MK, Tierney DS, Kuzma P, Pentikis HS. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol. 2005;45:1245–9.

    Article  CAS  PubMed  Google Scholar 

  46. Shore N, Cookson MS, Gittelman MC. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012;109:226–32.

    Article  CAS  PubMed  Google Scholar 

  47. Tan SH, Wolff AC. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer. 2007;7:455–64.

    Article  CAS  PubMed  Google Scholar 

  48. Jonat W. Goserelin (Zoladex)—its role in early breast cancer in pre- and perimenopausal women. Br J Cancer. 2001;85:1–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–11.

    Article  CAS  PubMed  Google Scholar 

  50. Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson JF, Blamey RW. Zoladex plus tamoxifen versus zoladex alone in pre- and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol. 1990;37:989–95.

    Article  CAS  PubMed  Google Scholar 

  51. Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, Sagara Y, Ohno S, Tsuyuki S, Mase T, Teramukai S. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Oncol Rep. 2013;29:1707–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Wang J, Xu B, Yuan P, Ma F, Li Q, Zhang P, Cai R, Fan Y, Luo Y, Li Q. Phase II trial of goserelin and exemestane combination therapy in premenopausal women with locally advanced or metastatic breast cancer. Medicine (Baltimore). 2015;94:e1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D’Alonzo A, Canavese G, Pronzato P, Bruzzi P. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675–83.

    Article  PubMed  CAS  Google Scholar 

  54. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L, GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632–40.

    Article  CAS  PubMed  Google Scholar 

  55. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3:S10–4.

    PubMed  PubMed Central  Google Scholar 

  57. Van Poppel H, Tombal B, De La Rosette J, Persson B, Jensen J, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker—results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–13.

    Article  PubMed  CAS  Google Scholar 

  58. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl. 2005;4:14–9.

    Article  CAS  Google Scholar 

  59. Tombal B, Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl. 2008;7:15–21.

    Article  CAS  Google Scholar 

  60. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–8.

    Article  CAS  PubMed  Google Scholar 

  61. Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015;193:1956–62.

    Article  CAS  PubMed  Google Scholar 

  62. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–73.

    Article  CAS  PubMed  Google Scholar 

  63. Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009;104:1580–4.

    Article  CAS  PubMed  Google Scholar 

  64. Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol. 2003;3:660–6.

    Article  CAS  PubMed  Google Scholar 

  65. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165:1585–9.

    Article  CAS  PubMed  Google Scholar 

  66. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB, Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58:756–61.

    Article  CAS  PubMed  Google Scholar 

  67. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology. 2008;71:1001–6.

    Article  PubMed  Google Scholar 

  68. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009;20:43–50.

    Article  CAS  PubMed  Google Scholar 

  69. Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol. 2012;19:594–601.

    Article  PubMed  CAS  Google Scholar 

  70. Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol. 2012;42:477–84.

    Article  PubMed  Google Scholar 

  71. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–8.

    Article  CAS  PubMed  Google Scholar 

  72. Iversen P, Damber JE, Malmberg A, Persson BE, Klotz L. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. Ther Adv Urol. 2016;8:75–82.

    Article  CAS  PubMed  Google Scholar 

  73. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–42.

    Article  CAS  PubMed  Google Scholar 

  74. Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3:127–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–52.

    Article  CAS  PubMed  Google Scholar 

  76. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47:30–9.

    Article  CAS  PubMed  Google Scholar 

  77. Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822–40.

    Article  CAS  PubMed  Google Scholar 

  79. Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:1556–7.

    Article  PubMed  CAS  Google Scholar 

  80. Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015;75:847–58.

    Article  CAS  PubMed  Google Scholar 

  81. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.

    Article  CAS  PubMed  Google Scholar 

  82. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  83. Pokuri VK, Fong MK, Iyer R. Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors. Curr Oncol Rep. 2016;18:7.

    Article  PubMed  CAS  Google Scholar 

  84. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S, Frascati Consensus Conference participants. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8–19.

    Article  CAS  PubMed  Google Scholar 

  85. Öberg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:124–30.

    Google Scholar 

  86. Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int. 2015;2015:917968.

    PubMed  PubMed Central  Google Scholar 

  87. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2011;317:664–73.

    Article  CAS  PubMed  Google Scholar 

  88. Muller A, Homey B, Soto Ha Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

    Article  CAS  PubMed  Google Scholar 

  89. Kitamura T, Pollard JW. Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res. 2015;100:266–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol. 2008;9:953–9.

    Article  CAS  PubMed  Google Scholar 

  91. Kraemer S, Alampour-Rajabi S, El Bounkari O, Bernhagen J. Hetero-oligomerization of chemokine receptors: diversity and relevance for function. Curr Med Chem. 2013;20:2524–36.

    Article  CAS  PubMed  Google Scholar 

  92. Massara M, Bonavita O, Mantovani A, Locati M, Bonecchi R. Atypical chemokine receptors in cancer: friends or foes? J Leukoc Biol. 2016;99:927–33.

    Article  CAS  PubMed  Google Scholar 

  93. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27:11–20.

    Article  CAS  PubMed  Google Scholar 

  94. Bayry J, Tartour E, Tough DF. Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. Trends Pharmacol Sci. 2014;35:163–5.

    Article  CAS  PubMed  Google Scholar 

  95. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293–8.

    Article  CAS  PubMed  Google Scholar 

  96. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–73.

    Article  CAS  PubMed  Google Scholar 

  97. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591–8.

    Article  CAS  PubMed  Google Scholar 

  98. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.

    Article  CAS  PubMed  Google Scholar 

  99. Yonekura K, Kanzaki T, Gunshin K, Kawakami N, Takatsuka Y, Nakano N, Tokunaga M, Kubota A, Takeuchi S, Kanekura T, Utsunomiya A. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41:239–44.

    Article  CAS  PubMed  Google Scholar 

  100. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, Otsuka E, Henzan H, Kato K, Tomoyose T, Yamamoto H, Kurosawa S, Matsuoka K, Yamaguchi T, Fukuda T. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426–33.

    Article  PubMed  Google Scholar 

  101. Ueda R. Clinical application of anti-CCR4 monoclonal antibody. Oncology. 2015;89:16–21.

    Article  PubMed  Google Scholar 

  102. Mishan MA, Ahmadiankia N. Bahrami AR.CXCR4 and CCR7: two eligible targets in targeted cancer therapy. Cell Biol Int. 2016;40:955–67.

    Article  CAS  PubMed  Google Scholar 

  103. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 2014;28(352):36–53.

    Article  CAS  Google Scholar 

  104. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

    CAS  PubMed  Google Scholar 

  105. Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao Y-J, Wiggins IP, Conley J, MacFarland RT. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 2007;51:2351–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Liu T, Li X, You S, Bhuyan SS, Dong L. Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice. Exp Hematol Oncol. 2016;5:19.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, Walenkamp AM. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 2012;14:709–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate. 2015;75:1227–46.

    Article  CAS  PubMed  Google Scholar 

  109. Wong D, Korz W, Merzouk A, Salari H. A peptide antagonist of chemokine receptor CXCR4 reduces tumor metastasis in a murine orthotopic model of human prostate cancer. Cancer Res. 2006;66:511.

    Article  Google Scholar 

  110. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther. 2009;8:1893–905.

    Article  CAS  PubMed  Google Scholar 

  111. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009;69:1460–9.

    Article  CAS  PubMed  Google Scholar 

  112. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009;155:231–6.

    Article  CAS  PubMed  Google Scholar 

  113. Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, Reichelt U, Kaifi JT, Izbicki JR, Gros SJ. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res. 2013;182:250–6.

    Article  CAS  PubMed  Google Scholar 

  114. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201–11.

    Article  CAS  PubMed  Google Scholar 

  115. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009;1:761–7.

    Google Scholar 

  116. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007;25:2158–66.

    Article  CAS  PubMed  Google Scholar 

  117. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011;39:282–92.

    Article  CAS  PubMed  Google Scholar 

  118. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144(1167–1175):e1.

    Google Scholar 

  119. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7:e34038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, Cohen LJ, Korman AJ, Cardarelli PM. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–66.

    Article  CAS  PubMed  Google Scholar 

  121. Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, Stille JR, Saleh M, Thornton D. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20:3581–8.

    Article  CAS  PubMed  Google Scholar 

  122. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7:28697–710.

    PubMed  PubMed Central  Google Scholar 

  123. Sharrack B, Leach T, Jacobson E, Donaldson DD, Xu X, Hu M. Frequent MRI study of a novel CCR2 antagonist in relapsing-remitting multiple sclerosis. Ann Neurol. 2007;62:S74–5.

    Google Scholar 

  124. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008;58:1931–9.

    Article  CAS  PubMed  Google Scholar 

  125. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res. 2013;19:3404–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73:1128–41.

    Article  CAS  PubMed  Google Scholar 

  127. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059–87.

    Article  CAS  PubMed  Google Scholar 

  128. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell. 2008;15:801–12.

    Article  CAS  PubMed  Google Scholar 

  129. Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2016;38:333–44.

    Article  CAS  PubMed  Google Scholar 

  130. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer. 2006;42:437–45.

    Article  CAS  PubMed  Google Scholar 

  131. Yun JI, Kim HR, Park H, Kim SK, Lee J. Small molecule inhibitors of the Hedgehog signaling pathway for the treatment of cancer. Arch Pharm Res. 2012;35:1317–33.

    Article  CAS  PubMed  Google Scholar 

  132. Ng JM, Curran T. The Hedgehog’s tale: developing strategies for targeting cancer. Nat Rev Cancer. 2011;11:493–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164–72.

    Article  Google Scholar 

  136. Tang JY, Mackay-Wiggan J, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the Hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–28.

    Article  CAS  PubMed  Google Scholar 

  138. Proctor AE, Thompson LA, O’Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014;48:99–106.

    Article  CAS  PubMed  Google Scholar 

  139. Collier NJ, Ali FR, Lear JT. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Expert Rev Anticancer Ther. 2016;16:1011–8.

    Article  CAS  PubMed  Google Scholar 

  140. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Tibes R. Sonidegib phosphate: new approval for basal cell carcinoma. Drugs Today (Barc). 2016;52:295–303.

    Article  CAS  PubMed  Google Scholar 

  142. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Yang Z, Ma H, Sun Z, Luo L, Tian S, Zheng J, Zhang X. Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors. Bioorg Med Chem Lett. 2015;25:3665–70.

    Article  CAS  PubMed  Google Scholar 

  144. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2:51ra70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, Wainwright BJ, McGovern K, Olson JM. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci USA. 2012;109:7859–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Campbell VT, Nadesan P, Ali SA, Wang CY, Whetstone H, Poon R, Wei Q, Keilty J, Proctor J, Wang LW, Apte SS, McGovern K, Alman BA, Wunder JS. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol Cancer Ther. 2014;13:1259–69.

    Article  CAS  PubMed  Google Scholar 

  147. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011;6:e28077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD, Sage J. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011;17:1504–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19:2766–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016;53:74–9.

    Article  CAS  PubMed  Google Scholar 

  152. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A phase I study of FOLFIRINOX plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 2016;45:370–5.

    Article  CAS  PubMed  Google Scholar 

  153. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015;56:2092–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett. 2011;3:106–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  155. Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O’Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2:e339–46.

    Article  PubMed  Google Scholar 

  157. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:1044–51.

    Article  CAS  PubMed  Google Scholar 

  158. Gonnissen A, Isebaert S, Haustermans K. Targeting the Hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015;6:13899–913.

    Article  PubMed  PubMed Central  Google Scholar 

  159. Di Magno L, Coni S, Di Marcotullio L, Canettieri G. Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. Biochim Biophys Acta. 2015;1856:62–72.

    PubMed  Google Scholar 

  160. Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014;2014:292376.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  161. Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D, Bruno A, Baldelli F, Donini A, Fiorucci S. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013;6:784–93.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72:3839–50.

    Article  PubMed  CAS  Google Scholar 

  163. Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 2013;8:e53992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res. 2014;74:7103–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell. 2016;29:587–601.

    Article  CAS  PubMed  Google Scholar 

  166. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201–6.

    Article  CAS  PubMed  Google Scholar 

  167. Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK. β-blockers: a new role in cancer chemotherapy? Expert Opin Investig Drugs. 2013;22:1359–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Tang J, Li Z, Lu L, Cho CH. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23:533–42.

    Article  CAS  PubMed  Google Scholar 

  169. Laken PA. Infantile hemangiomas: pathogenesis and review of propranolol use. Adv Neonatal Care. 2016;16:135–42.

    Article  PubMed  Google Scholar 

  170. Rosanò L, Spinella F, Bagnato A. The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am J Physiol Regul Integr Comp Physiol. 2010;299:395–404.

    Article  CAS  Google Scholar 

  171. Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro Oncol. 2016;18:486–96.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Sestito R, Cianfrocca R, Rosanò L, Tocci P, Di Castro V, Caprara V, Bagnato A. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sci. 2016;159:43–8.

    Article  CAS  PubMed  Google Scholar 

  173. Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin Cancer Res. 2015;21:4630–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Fitzner B, Brock P, Holzhüter SA, Nizze H, Sparmann G, Emmrich J, Liebe S, Jaster R. Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells. Dig Dis Sci. 2009;54:309–20.

    Article  CAS  PubMed  Google Scholar 

  175. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer. 2010;9:69.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  176. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3–14.

    Article  CAS  PubMed  Google Scholar 

  177. Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38:33–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Miyajima A, Kosaka T, Kikuchi E, Oya M. Renin-angiotensin system blockade: Its contribution and controversy. Int J Urol. 2015;22:721–30.

    Article  PubMed  Google Scholar 

  179. Fan F, Tian C, Tao L, Wu H, Liu Z, Shen C, Jiang G, Lu Y. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. Biomed Pharmacother. 2016;83:704–11.

    Article  CAS  PubMed  Google Scholar 

  180. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006;12:2888–93.

    Article  CAS  PubMed  Google Scholar 

  181. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62:4176–9.

    CAS  PubMed  Google Scholar 

  182. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005;10:405–10.

    Article  CAS  PubMed  Google Scholar 

  183. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623–35.

    Article  CAS  Google Scholar 

  184. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T. Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. Cardiology. 2012;123:240–7.

    Article  CAS  PubMed  Google Scholar 

  185. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–80.

    Article  PubMed  PubMed Central  Google Scholar 

  186. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2:1030–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy

    Rosamaria Lappano & Marcello Maggiolini

Authors
  1. Rosamaria Lappano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcello Maggiolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rosamaria Lappano or Marcello Maggiolini.

Ethics declarations

Funding

This work was supported by Associazione Italiana per la Ricerca sul Cancro (Grant No. 16719/2015).

Conflict of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lappano, R., Maggiolini, M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 77, 951–965 (2017). https://doi.org/10.1007/s40265-017-0738-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0738-9

Keywords

Search

Navigation